March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for ...
March 4, 2022 – NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of ...
February 24, 2022 — The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of ...
January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...
January 4, 2022 — The Omicron variant, as of Dec. 25, made up 58.6% of new COVID-19 infections in the U.S., according to ...
January 4, 2022 —  The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first ...
January 3, 2022 — The U.S. Food and Drug Administration (FDA) recently revised its Janssen COVID-19 Vaccine Fact Sheets ...
December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...
The following are the late-breaking science presentation sessions at the 2021 American Heart Association (AHA) 2021 ...
November 23, 2021 — The antiplatelet drug class of P2Y12 inhibitors that block the activity of platelets and prevents ...
November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...
Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at ...
November 19, 2021 — Adults treated with empagliflozin during hospitalization for acute heart failure experienced a ...
November 19, 2021 — A high dose of a purified omega-3 fatty acid, available by prescription only, was well tolerated ...